


Ba/F3 Model Carrying HER2 A775_G776insYVMA C805S



2024.10



HER2 exon20 YVMAlns and C805S secondary mutation



Nature Reviews Clinical Oncology volume 19, pages51–69 (2022)



- ERBB2 (or HER2) is associated with a limited range of exon 20 mutations, primarily consisting short duplications or insertions. Notably, 90% of these mutations occur between amino acids 772 and 780, with the YVMA insertion duplication variants being the most common.
- In recent years, ongoing research has led to the development of various treatment drugs targeting EGFR exon 20 insertions, such as pozoitinib, luminespib, mobocertinib, etc.
- Secondary mutations in HER2 (C805S) that mediated acquired drug resistance in drug-sensitive EGFR or HER2 exon 20 insertion models.

Establishment of Ba/F3 HER2 A775_G776insYVMA C805S cell line



- The full length (3780bp) was validated by 6 pairs of primer. No unwanted mutation was detected.
- The identification results of interested region were shown in right figure.



Inhibitors in Ba/F3 HER2 A775_G776insYVMA C805S cell line





Compound	Cell line	AbsIC50 (nM)	ReIC50 (nM)	Bottom (%)	Top (%)
Poziotinib	Ba/F3 HER2 A775_G776insYVMA	1.97	2.38	7.68	100.00
	Ba/F3 HER2 A775_G776insYVMA C805S	613.31	623.90	-2.10	99.97
Mobocertinib	Ba/F3 HER2 A775_G776insYVMA	17.34	20.25	12.02	100.00
	Ba/F3 HER2 A775_G776insYVMA C805S	2842.10	2975.00	-2.67	99.92

Inhibitors in Ba/F3 HER2 A775_G776insYVMA C805S model

BaF3 HER2 A775_G776insYVMA



BaF3 HER2 A775_G776insYVMA C805S





OUR COMMITMENT

Improving Health. Making a Difference.

For questions and requests, please email to Pharmacology-BD-Translation@wuxiapptec.com



<https://onco.wuxiapptec.com>